Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Auto Immune Disease Clear all
Completed Phase 2 Interventional Results available

A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients

NCT03560739
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ofatumumab with PRF, ofatumumab with AI
Combination Product
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Fullerton, California • Aurora, Colorado • Basalt, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Jun 10, 2026, 6:28 AM EDT
Completed Phase 1 Interventional

Fecal Microbial Transplant (FMT) for Sjogrens Syndrome

NCT03926286
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
FMP-30
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Jun 10, 2026, 6:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug

NCT03014674
View directory record Official record
Conditions
Asthma
Interventions
Lyophilized mepolizumab, Liquid mepolizumab, Prefilled autoinjector, Prefilled Safety Syringe
Biological · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jun 10, 2026, 6:28 AM EDT
Completed Phase 2 Interventional

HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

NCT04975698
View directory record Official record
Conditions
HIV Associated Lymphoma
Interventions
HST-NEETs, Bone Marrow Transplant
Biological
Lead sponsor
Catherine Bollard
NIH
Eligibility
15 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Duarte, California • Washington D.C., District of Columbia • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jun 10, 2026, 6:28 AM EDT
Completed Phase 2 Interventional

Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00425321
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
RWJ-445380 100 mg, RWJ-445380 200 mg, RWJ-445380 300 mg, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Jun 10, 2026, 6:28 AM EDT
Completed Phase 3 Interventional Results available

Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma

NCT01241708
View directory record Official record
Conditions
Multiple Myeloma, Auto Stem Cell Transplant
Interventions
Bortezomib
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 75 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Jun 10, 2026, 6:28 AM EDT
Completed Phase 2 Interventional Results available

Tandem Auto-Allo Transplant for Lymphoma

NCT01181271
View directory record Official record
Conditions
Diffuse, Large B-Cell, Lymphoma, Lymphoma, Low-Grade, T-Cell Lymphoma, Mantle-Cell Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Interventions
Busulfan (conditioning for AUTO transplant), Etoposide (conditioning for AUTO transplant), Cyclophosphamide (conditioning for AUTO transplant), Mesna (prior to AUTO transplant), autologous (auto) peripheral blood stem cell transplantation, Neupogen, Fludarabine (conditioning for ALLO Transplant), Busulfan (conditioning for ALLO Transplant), non-myeloablative allogeneic (allo) transplant, Tacrolimus, Sirolimus, Methotrexate
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Jun 10, 2026, 6:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK/PD Study of IN-001 Sublingual Spray in Healthy Adults

NCT07210320
View directory record Official record
Conditions
Food Allergy, Anaphylaxis, Food Hypersensitivity, Food Allergy Peanut
Interventions
Epinephrine Auto-Injector 0.3 mg/0.3 mL, Epinephrine 0.3 mg intramuscular manual injection via a syringe and needle, IN-001 9.06 mg Sublingual Spray, IN-001 13.59 mg Sublingual Spray
Drug
Lead sponsor
Insignis Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 10, 2026, 6:28 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS)

NCT04868968
View directory record Official record
Conditions
Familial Cold Autoinflammatory Syndrome
Interventions
DFV890
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Jun 10, 2026, 6:28 AM EDT
Terminated Phase 2 Interventional Results available

An Open-label Safety Study of Lusutrombopag (S-888711) in Adults With Chronic Immune Thrombocytopenia (ITP)

NCT01129024
View directory record Official record
Conditions
Immune Thrombocytopenia
Interventions
Lusutrombopag
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Anaheim, California • Los Angeles, California • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Jun 10, 2026, 6:28 AM EDT
Withdrawn No phase listed Observational

Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis

NCT01845467
View directory record Official record
Conditions
Cellular Diagnosis, Pancreatic Cancer, Autoimmune Pancreatitis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
19 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Jun 10, 2026, 6:28 AM EDT
Not listed Phase 1Phase 2 Interventional

Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM)

NCT03795597
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Busulfan IV, Melphalan IV
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jun 10, 2026, 6:28 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients

NCT01351480
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
abatacept
Biological
Lead sponsor
Arthritis & Rheumatic Disease Specialties Research
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Jun 10, 2026, 6:28 AM EDT
Recruiting Phase 2 Interventional

Auto Stem Cell Transplant for Lymphoma Patients

NCT03125642
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Etoposide, BCNU, AraC, Melphalan, Peripheral blood stem cell transplantation, G-CSF, Cyclophosphamide, Total Body Irradiation
Drug · Procedure · Biological + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Jun 10, 2026, 6:28 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis

NCT02852967
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
Belumosudil, Placebo
Drug
Lead sponsor
Kadmon Corporation, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
14
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Jun 10, 2026, 6:28 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home

NCT02918071
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
14
States / cities
Northridge, California • Riverside, California • Westminster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Jun 10, 2026, 6:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS

NCT04018599
View directory record Official record
Conditions
Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn Disease, Ulcerative Colitis, Plaque Psoriasis, Pediatric Plaque Psoriasis, Pediatric Crohns Disease, Hidradenitis Suppurativa, Non-infectious Uveitis
Interventions
40 mg MSB11022
Drug
Lead sponsor
Fresenius Kabi SwissBioSim GmbH
Industry
Eligibility
18 Years to 55 Years
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Jun 10, 2026, 6:28 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells

NCT03628612
View directory record Official record
Conditions
Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy, Multiple Myeloma, DLBCL, ALL, Adult and Pediatric, T Cell Lymphoma
Interventions
AUTO CAR T cell therapy
Biological
Lead sponsor
Autolus Limited
Industry
Eligibility
1 Year and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2043
U.S. locations
3
States / cities
Miami, Florida • St Louis, Missouri • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jun 10, 2026, 6:28 AM EDT
Active, not recruiting Phase 2 Interventional

Descartes-08 for Patients With Systemic Lupus Erythematosus

NCT06038474
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Descartes-08
Drug
Lead sponsor
Cartesian Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Oceanside, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 10, 2026, 6:28 AM EDT
Withdrawn Phase 2 Interventional

Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)

NCT00230035
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT), Plasmapheresis, Rabbit anti-thymocyte globulin, Methylprednisolone, Growth colony stimulating factor (G-CSF), Corticosteroids, Mycophenolate mofetil, Azathioprine, Intravenous immunoglobulin, Methotrexate, Rituximab, Leflunomide
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
5
States / cities
La Jolla, California • Los Angeles, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Jun 10, 2026, 6:28 AM EDT
Completed Not applicable Interventional Results available

Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma

NCT01050790
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Azacitidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 69 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Jun 10, 2026, 6:28 AM EDT
Recruiting No phase listed Observational

Paradoxical Tuberculosis Reactions in Patients Without HIV Infection

NCT04052022
View directory record Official record
Conditions
Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jun 10, 2026, 6:28 AM EDT
Completed No phase listed Observational

The CARRA Registry

NCT01697254
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Juvenile Ankylosing Spondylitis, Juvenile Dermatomyositis, Localized Scleroderma, Systemic Sclerosis, Vasculitis, Sarcoid, Fibromyalgia, Primary, Auto-inflammatory Disease, Idiopathic Uveitis Idiopathic
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
9,587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Jun 10, 2026, 6:28 AM EDT
Terminated Phase 2 Interventional Results available

An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease

NCT01009281
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
AIN457
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Bristol, Connecticut • Great Neck, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Jun 10, 2026, 6:28 AM EDT